NeuroSurvival Technologies develops pharmaceutical tools to detect and modulate cellular "suicide".
The investment fund of the international pharmaceutical firm Johnson and Johnson has invested $2.5 million in the Israeli company NeuroSurvival Technologies, (NST) at a value of $52.5 million after money.
NeuroSurvival Technologies develops pharmaceutical tools to detect and modulate cellular "suicide". The method has clinical applications for a wide range of diseases. The company was founded in 1996 by Ilan Ziv, who serves as president and CEO. The chairman of the board is CEO of Clal Biotechnology Industries Ltd., David Haselkorn,
NeuroSurvival Technologies recently raised $5 million at a value of $50 million after money. The main shareholders are Bergal R&D (31.8%), Clal Biotechnology Industries (5.2%), Federman Holdings (5.2%), Poalim Investments Ltd. (5.2%), Technorov Holdings (5.2%), and Modgal-Tech (2.9%).
Modgal-Tech 2000 is fully owned by the public company Modgal which is traded on the Tel Aviv Stock Exchange and operates as the investment and holding arm for venture capital, mainly in high-tech and biotechnology. Its chairman is Aria Zaif.
Published by Israel's Business Arena on July 19, 2000